The response rate to this drug appears to correlate with TET2, IDH1/2, and DNMT3A mutations, and thus, is of particular value for AITL and PTCL-NOS [57]. The gene discussed is DNMT3A; the disease is angioimmunoblastic T-cell lymphoma.